{
    "nctId": "NCT00976365",
    "briefTitle": "Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer",
    "officialTitle": "Phase IIa Study of Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "QOL",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed breast cancer with clinical evidence.\n* Life expectancy of at least 4 weeks.\n\nExclusion Criteria:\n\n* Any Uncontrolled infection.\n* Lupus erythematosus.\n* Malignant tumor.",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}